Skip to main content

Table 1 Patients characteristic

From: ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

N° of patients

26

Age, mean years (range)

66 (49-79)

Gender, n° of patients (%)

 Male

21 (80.8%)

 Female

5 (19.2%)

Months of follow-up, median

36

Histopathological stage, n° of patients (%)

 TaG3

4 (15.4%)

 T1G3

14 (53.8%)

 Cis

4 (15.4%)

 Ta/T1G3 + Cis

4 (15.4%)

Time from first diagnosis, months range

3-9